siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy
ConclusionInhibition of E6 oncogene expression and subsequent E6-siRNA with Oxaliplatin combination therapy could be a novel strategy for cervical cancer treatment.Graphical Abstract
Source: European Journal of Medical Research - Category: Research Source Type: research
More News: Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Eloxatin | Genetics | Genital Warts | Nanotechnology | Research | Study